

## Authors reply

Sir,

### Use of Intravenous Fat Emulsions in Adult Critically ill Patients: Does omega 3 make a difference?: Response letter to the editor

We have read with interest the letter to the editor by Norbert Nagel and Anna Harder from B Braun Melsungen AG, commenting on Table 2: "Characteristics of commercially available intravenous lipid emulsions used in reported randomized controlled trials".

We acknowledge the amount of EPA and DHA for SMOFlipid and Lipoplus 20% is a controversial topic as different values have been published by various authors as alluded to by Nagel and Harder. Kreyman et al. 2017<sup>1</sup> also documented the variations in EPA and DHA values in the different lipid emulsions and chose to report a range, as opposed to absolute values, due to the variation in the fish oils used for production. This variation was also demonstrated in the Driscoll et al. 2009 publication<sup>2</sup>.

In order to obviate such controversies in the literature, we agree that it might be preferable to report ranges rather than absolute values.

**Veronique Donoghue<sup>a</sup>, Renée Blaauw<sup>b</sup> and Maryke Spruyt<sup>c</sup>**

<sup>a</sup> Masters student, Division of Human Nutrition, Faculty of Medicine and Health Sciences, Stellenbosch University South Africa

<sup>b</sup> Division of Human Nutrition, Faculty of Medicine and Health Sciences, Stellenbosch University South Africa

<sup>c</sup> Head, Clinical Department: Critical Care, Faculty of Health Sciences, University of the Free State South Africa

### References:

1. Kreyman KG, Heyland DK, de Heer G, Elke G. Intravenous fish oil in critically ill and surgical patients - Historical remarks and critical appraisal. Clin Nutr. <http://dx.doi.org/10.1016/j.clnu.2017.07.006>
2. Driscoll, DF, Ling, P-R, Bristrian BR. Pharmacopeial compliance of fish oil-containing parenteral lipid emulsions mixtures: Globule size distribution (GSD) and fatty acid analyses. International Journal of Pharmaceutics. 2009;379:125-130

## News

## Corrigendum

In the review on "Use of Intravenous Fat Emulsions in Adult Critically Ill Patients: Does omega 3 make a difference?" by Donoghue et al. in the South African Journal of Clinical Nutrition 2017; 30(3):38-48, Table 2, (in its indicated components) is corrected to read as follows:

**Table 2:** Characteristics of commercially available intravenous lipid emulsions used in reported randomized controlled trials (1-9).

Composition Abbreviation	Intralipid 20% SO	Lipofundin 20% MCT/LCT	ClinOleic 20% OO/SO	SMOFlipid 20% SMOF	Omegaven 10% FO Not available in SA	Lipoplus 20% MCT/LCT/FO Not available in SA
<b>% Fatty acids</b>						
EPA	0	0	0	3.0-4.7	19.2	3.5-3.7
DHA	0	0	0	2.0-4.4	12.1	2.5

Abbreviations: SO: Soybean oil; MCT: Medium Chain Triglycerides; OO: Olive Oil; FO: Fish oil; EPA: Eicosapentaenoic Acid; DHA: Docosahexaenoic acid

The corrigendum is published to provide a composition range, as opposed to absolute values where appropriate, due to the variation in the inherent content of the fish oils used for the production of lipid emulsions, as well as to obviate any controversies arising therefrom.